Equities

Neovacs SA

Neovacs SA

Actions
  • Price (EUR)0.6698
  • Today's Change-0.010 / -1.50%
  • Shares traded7.64k
  • 1 Year change-100.00%
  • Beta0.9470
Data delayed at least 15 minutes, as of Mar 28 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The Company operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.

  • Revenue in EUR (TTM)53.48k
  • Net income in EUR-5.00m
  • Incorporated1992
  • Employees23.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
MagForce AG351.98k-10.57m47.89k69.00--0.0018--0.1361-0.3531-0.35310.01180.89670.00553.470.85325,101.16-16.47-3.78-31.53-6.78-89.9525.30-3,004.22-295.230.0321-1.970.2485---43.33-5.77-171.71------
Pharnext SCA150.00k-31.55m135.03k44.00------0.9002-26,278,830.00-26,278,830.00171.43-17,532.990.0186--0.0298---391.03-128.26---367.63-22.54---21,035.67-4,413.23---------99.34---25.57---29.58--
European Institute of Science AB52.22k-236.39k144.77k0.00--0.8865--2.77-8.00-8.001.775.540.17280.84798.63---78.21-93.04-82.77-103.1462.3367.01-452.67-518.8210.54------13.698.540.4062------
Paion AG-100.00bn-100.00bn200.46k64.00---------------0.4074-----------24.86---34.32-------52.400.5078--1.17--366.4241.7497.34--129.37--
Neovacs SA53.48k-5.00m239.15k23.000.000.00--4.4714,869,250.0014,869,250.00764.00364,547.300.001--0.55612,546.67-9.24-36.05-10.24-46.06-917.26-3,215.82-9,344.13-74,596.98----0.0286---95.08--70.02--3.58--
Eurocine Vaccines AB435.00-1.31m263.91k3.00------606.43-0.1472-0.14720.00005-0.00180.0007--0.002---199.76-83.17-323.19-97.89-199,780.00---301,180.00--------------8.95------
Redwood Pharma AB0.00-1.23m282.96k1.00--0.2393-----9.25-9.250.005.120.00----0.00-86.77-95.03-98.20-123.04-----------19.99---------8.78---5.11--
Diagonal Bio AB2.00k-1.02m294.70k4.00--0.1594--147.22-0.327-0.3270.00060.53150.0007--2.005,750.00-37.35---44.49---41,604.35---50,769.57--0.5105-104.20-----88.67--27.75------
CoDon AG9.84m-14.13m315.34k134.00--0.0478--0.032-0.5513-0.55130.40180.24680.51610.986410.1073,432.84-74.08-41.86-86.85-48.5394.1091.39-143.53-139.570.8393-21.920.4887--57.2811.8632.79--24.07--
XP Chemistries AB57.77k-699.68k321.18k2.00--0.1437--5.56-0.2297-0.22970.0190.2750.0230.20845.99331,845.00-27.79---29.36--50.57---1,211.24--5.79-------37.14---1.55------
QuiaPEG Pharmaceuticals Holding AB0.00-1.44m376.08k8.00--0.2833-----3.45-3.450.000.20470.00-------50.53-95.67-100.54-207.86--262.59---5,002.50---15.340.00------17.75--47.06--
SoftOx Solutions AS1.24m-1.42m398.77k----0.1713--0.3224-1.60-1.601.402.630.1663--4.67---19.12-51.04-30.18-61.72-----114.95-610.690.3851--0.00---9.97489.41-8.77--26.71--
Data as of Mar 28 2024. Currency figures normalised to Neovacs SA's reporting currency: Euro EUR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.